# A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Source: https://onco.cc/trials/nct07417189/  
OnCo record `nct07417189` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ABSK141-400mg in advanced solid tumours, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) is a phase 1/2 interventional study registered as NCT07417189 by Abbisko Therapeutics Co, Ltd, with 401 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg and ABSK141-Recommended Phase 2 dose (RP2D).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07417189
- Phase: 1/2
- Setting: A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 401

## Sources

- ClinicalTrials.gov NCT07417189: https://clinicaltrials.gov/study/NCT07417189

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct07417189.json